BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fukui H. Do vasopressin V2 receptor antagonists benefit cirrhotics with refractory ascites? World J Gastroenterol 2015; 21(41): 11584-11596 [PMID: 26556988 DOI: 10.3748/wjg.v21.i41.11584] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
Number Citing Articles
1 Madoff DC, Cornman-Homonoff J, Fortune BE, Gaba RC, Lipnik AJ, Yarmohammadi H, Ray CE Jr. Management of Refractory Ascites Due to Portal Hypertension: Current Status. Radiology 2021;298:493-504. [PMID: 33497318 DOI: 10.1148/radiol.2021201960] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Kawaratani H, Fukui H, Yoshiji H. Treatment for cirrhotic ascites. Hepatol Res. 2017;47:166-177. [PMID: 27363974 DOI: 10.1111/hepr.12769] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
3 Tajiri K, Tokimitsu Y, Ito H, Atarashi Y, Kawai K, Minemura M, Yasumura S, Takahara T, Shimizu Y, Sugiyama T. Survival Benefit of Tolvaptan for Refractory Ascites in Patients with Advanced Cirrhosis. Dig Dis 2018;36:314-21. [PMID: 29852495 DOI: 10.1159/000489258] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
4 Bellos I, Kontzoglou K, Perrea DN. Predictors of tolvaptan short-term response in patients with refractory ascites: A meta-analysis. J Gastroenterol Hepatol 2020;35:182-91. [PMID: 31323125 DOI: 10.1111/jgh.14784] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
5 Noda Y, Sasaki S. Updates and Perspectives on Aquaporin-2 and Water Balance Disorders. Int J Mol Sci 2021;22:12950. [PMID: 34884753 DOI: 10.3390/ijms222312950] [Reference Citation Analysis]
6 Fukui H, Kawaratani H, Kaji K, Takaya H, Yoshiji H. Management of refractory cirrhotic ascites: challenges and solutions. Hepat Med. 2018;10:55-71. [PMID: 30013405 DOI: 10.2147/hmer.s136578] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
7 Kasztelan-Szczerbinska B, Cichoz-Lach H. Refractory ascites-the contemporary view on pathogenesis and therapy. PeerJ 2019;7:e7855. [PMID: 31637125 DOI: 10.7717/peerj.7855] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Sbardella E, Isidori AM, Arnaldi G, Arosio M, Barone C, Benso A, Berardi R, Capasso G, Caprio M, Ceccato F, Corona G, Della Casa S, De Nicola L, Faustini-Fustini M, Fiaccadori E, Gesualdo L, Gori S, Lania A, Mantovani G, Menè P, Parenti G, Pinto C, Pivonello R, Razzore P, Regolisti G, Scaroni C, Trepiccione F, Lenzi A, Peri A; the: Fluid and Electrolyte Disorders Club of the Italian Society of Endocrinology; Italian Society of Nephrology; and Italian Association of Medical Oncology. Approach to hyponatremia according to the clinical setting: Consensus statement from the Italian Society of Endocrinology (SIE), Italian Society of Nephrology (SIN), and Italian Association of Medical Oncology (AIOM). J Endocrinol Invest 2018;41:3-19. [PMID: 29152673 DOI: 10.1007/s40618-017-0776-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
9 Musso CG, Juarez R, Glassock RJ. Water, electrolyte, acid–base, and trace elements alterations in cirrhotic patients. Int Urol Nephrol 2018;50:81-9. [DOI: 10.1007/s11255-017-1614-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.4] [Reference Citation Analysis]
10 Kawaratani H, Fukui H, Moriya K, Noguchi R, Namisaki T, Uejima M, Kitade M, Takeda K, Okura Y, Kaji K. Predictive parameter of tolvaptan effectiveness in cirrhotic ascites. Hepatol Res. 2016; Epub ahead of print. [PMID: 27704665 DOI: 10.1111/hepr.12826] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
11 Filippatos TD, Makri A, Elisaf MS, Liamis G. Hyponatremia in the elderly: challenges and solutions. Clin Interv Aging 2017;12:1957-65. [PMID: 29180859 DOI: 10.2147/CIA.S138535] [Cited by in Crossref: 37] [Cited by in F6Publishing: 15] [Article Influence: 7.4] [Reference Citation Analysis]
12 Ling Q, Dai H, Zhuang R, Shen T, Wang W, Xu X, Zheng S. Predicting short-term survival after liver transplantation on eight score systems: a national report from China Liver Transplant Registry. Sci Rep 2017;7:42253. [PMID: 28198820 DOI: 10.1038/srep42253] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
13 Filippatos TD, Liamis G, Elisaf MS. Ten pitfalls in the proper management of patients with hyponatremia. Postgraduate Medicine 2016;128:516-22. [DOI: 10.1080/00325481.2016.1186488] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
14 Mori T, Ohsaki Y, Oba-yabana I, Ito S. Diuretic usage for protection against end-organ damage in liver cirrhosis and heart failure: Diuretic usage in volume overload diseases. Hepatol Res 2017;47:11-22. [DOI: 10.1111/hepr.12700] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
15 Miyazaki M, Yada M, Tanaka K, Senjyu T, Goya T, Motomura K, Kohjima M, Kato M, Masumoto A, Kotoh K. Efficacy of tolvaptan for the patients with advanced hepatocellular carcinoma. World J Gastroenterol 2017; 23(29): 5379-5385 [PMID: 28839438 DOI: 10.3748/wjg.v23.i29.5379] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]